David Miklos

Publications

• Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
  Logan, A. C., Vashi, N., Faham, M., Carlton, V., Kong, K., & Miklos, D. B. (2014). Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biology of blood and marrow transplantation , 20(9), 1307-1313.
• Clinical impact of H-Y alloimmunity
  Popli, R., Sahaf, B., Nakasone, H., Lee, J. Y. Y., & Miklos, D. B. (2014). Clinical impact of H-Y alloimmunity. IMMUNOLOGIC RESEARCH, 58(2-3), 249-258.
• Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
  Logan, A. C., Zhang, B., Narasimhan, B., Carlton, V., Zheng, J., & Miklos, D. B. (2013). Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. LEUKEMIA, 27(8), 1659-1665.
• A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., & Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. BLOOD, 121(24), 4955-4962.
  
• H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., & Miklos, D. B. (2013). H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3005-3010.
  
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.
  
• High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment Logan, A. C., Gao, H., Wang, C., Sahaf, B., Jones, C. D., & Miklos, D. B. (2011). High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(52), 21194-21199.
  
• Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L. X., Zorn, E., & Ritz, J. (2005). Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. BLOOD, 105(7), 2973-2978.
  
• Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Nickel, R. S., Hendrickson, J. E., Yee, M. M., Bray, R. A., Gebel, H. M., & Horan, J. T. (2015). Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. British journal of haematology, 170(2), 247-256.
  
• Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., & Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679-3687.
  
• Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans Nakasone, H., Tian, L., Sahaf, B., Kawase, T., Schoenrock, K., & Miklos, D. B. (2015). Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. BLOOD, 125(20), 3193-3201.
  
• Therapeutic benefits targeting B-cells in chronic graft-versus-host disease Nakasone, H., Sahaf, B., & Miklos, D. B. (2015). Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. INTERNATIONAL JOURNAL OF HEMATOLOGY, 101(5), 438-451.
  
• ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation Logan, A. C., Wang, Z., Alimoghaddam, K., Wong, R. M., Lai, T., & Miklos, D. B. (2015). ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(4), 746-754.
  
• A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor. Mahadeo, K. M., Weinberg, K. I., Abdel-Azim, H., Miklos, D. B., Killen, R., & Kapoor, N. (2015). A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor. Biology of blood and marrow transplantation , 21(3), 440-444.
  
• Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Fleischhauer, K., Fernandez-Viña, M. A., Wang, T., Haagenson, M., Battiwalla, M., & Spellman, S. R. (2014). Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Bone marrow transplantation, 49(9), 1176-1183.
  
• Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.
  
• Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation Dobbelstein, C., Ahn, K. W., Haagenson, M., Hale, G. A., Van Rood, J. J., & Lee, S. J. (2013). Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(5), 741-745.
  
• Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease Namboodiri, A. M., Nietert, P. J., Wadia, P. P., Miklos, D. B., & Pandey, J. P. (2012). Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease. VIRAL IMMUNOLOGY, 25(4), 338-340.
  
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.
  
• Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL Tseng, D., Jones, C. D., Anderson, M., Warnke, R., Zehnder, J. L., & Miklos, D. B. (2011). Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. BONE MARROW TRANSPLANTATION, 46(12), 1576-1578.
  
• Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.
  
• A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.
  
• Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation Porcheray, F., Miklos, D. B., Floyd, B. H., Sarantopoulos, S., Bellucci, R., & Zorn, E. (2011). Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. TRANSPLANTATION, 92(3), 359-365.
  
• The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age Dong, L., Wu, T., Gao, Z.-Y., Zhang, M.-J., Kan, F., & Lee, S. J. (2011). The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(8), 1205-1213.
  
• B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., & Engleman, E. G. (2011). B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. NATURE MEDICINE, 17(5), 610-U134.
  
• Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease Butte, A. J., Sigdel, T. K., Wadia, P. P., Miklos, D. B., & Sarwal, M. M. (2011). Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease. MOLECULAR & CELLULAR PROTEOMICS, 10(3).
  
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.
  
• Recombinant antigen microarrays for serum/plasma antibody detection. Wadia, P. P., Sahaf, B., & Miklos, D. B. (2011). Recombinant antigen microarrays for serum/plasma antibody detection. Methods in molecular biology (Clifton, N.J.), 723, 81-104.
  
• Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors Shaw, P. J., Kan, F., Ahn, K. W., Spellman, S. R., Aljurf, M., & Pulsipher, M. A. (2010). Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. BLOOD, 116(19), 4007-4015.
  
• H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births Nielsen, H. S., Wu, F., Aghai, Z., Steffensen, R., van Halteren, A. G., & Goulmy, E. (2010). H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births. HUMAN REPRODUCTION, 25(11), 2745-2752.
  
• Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637-639.
  
• Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Müller, A. Ms., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721-14726.
  
• Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.
  
• Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements Boyd, S. D., Gaeta, B. A., Jackson, K. J., Fire, A. Z., Marshall, E. L., & Collins, A. M. (2010). Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements. JOURNAL OF IMMUNOLOGY, 184(12), 6986-6992.
  
• Rituximab in hematopoietic cell transplantation Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971-982.
  
• Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation Wadia, P. P., Coram, M., Armstrong, R. J., Mindrinos, M., Butte, A. J., & Miklos, D. B. (2010). Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. BLOOD, 115(10), 2077-2087.
  
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.
  
• Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures Li, L., Wadia, P., Chen, R., Kambham, N., Naesens, M., & Butte, A. J. (2009). Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome'' measures. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(11), 4148-4153.
  
• B Cells and Transplantation: An Educational Resource Small, T. N., Robinson, W. H., & Miklos, D. B. (2009). B Cells and Transplantation: An Educational Resource. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(1), 104-113.
  
• H-Y antibody development associates with acute rejection in female patients with male kidney transplants Tan, J. C., Wadia, P. P., Coram, M., Grumet, F. C., Kambham, N., & Miklos, D. B. (2008). H-Y antibody development associates with acute rejection in female patients with male kidney transplants. TRANSPLANTATION, 86(1), 75-81.
  
• Renal pathology in hematopoietic cell transplantation recipients Troxell, M. L., Pilapil, M., Miklos, D. B., Higgins, J. P., & Kambham, N. (2008). Renal pathology in hematopoietic cell transplantation recipients. MODERN PATHOLOGY, 21(4), 396-406.
  
• Rituximab for steroid-refractory chronic graft-versus-host disease Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., & Alyea, E. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. BLOOD, 108(2), 756-762.
  
• Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., & Pavletic, S. Z. (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(2), 126-137.
  
• Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors Miklos, D. B., Kim, H. T., Zorn, E., Hochberg, E. P., Guo, L. X., & Ritz, J. (2004). Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. BLOOD, 103(1), 353-359.